Capstone Therapeutics (CAPS) Expected to Announce Earnings on Wednesday

Capstone Therapeutics (NASDAQ:CAPS) is projected to announce its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Capstone Therapeutics to post earnings of $0.12 per share and revenue of $20.3850 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 8:00 AM ET.

Capstone Therapeutics (NASDAQ:CAPS) last announced its quarterly earnings data on Wednesday, May 20th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). Capstone Therapeutics had a negative net margin of 41.26% and a negative return on equity of 114.15%. The company had revenue of $12.64 million for the quarter, compared to analysts’ expectations of $10.80 million.

Capstone Therapeutics Price Performance

NASDAQ CAPS opened at $0.29 on Tuesday. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.95 and a quick ratio of 0.29. The stock’s fifty day moving average price is $0.27 and its 200 day moving average price is $0.44. Capstone Therapeutics has a 1 year low of $0.23 and a 1 year high of $2.07. The company has a market cap of $4.48 million, a price-to-earnings ratio of -0.09 and a beta of -1.52.

Institutional Investors Weigh In On Capstone Therapeutics

An institutional investor recently bought a new stake in Capstone Therapeutics stock. DRW Securities LLC bought a new stake in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned approximately 1.51% of Capstone Therapeutics at the end of the most recent reporting period. 2.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Capstone Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.